Immix Biopharma develops CAR T cell therapies, led by NXC-201, for AL amyloidosis and other serious diseases. IMMX reports earnings on Fri, Nov 6, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for IMMX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in IMMX in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMMX is in one of them and how their past IMMX trades turned out.
Immix Biopharma is a biopharmaceutical company based in Los Angeles, California. It develops chimeric antigen receptor (CAR) T cell therapies, led by its candidate NXC-201, for AL amyloidosis, a serious disease in which an abnormal protein builds up in organs such as the heart and kidneys. The lead candidate is in clinical trials and is not yet approved for sale. The company's target patients have this disease or other serious conditions where CAR T therapy is not yet an approved treatment.
